Imugene | Cancer Immunotherapies

Turning a scientific idea into a therapy takes time.

Years of testing. Validation. Refinement.

Our latest data, alongside @10NewsAU coverage, shows the progress we are making step by step.

youtu.be/aasEY17FQIw?si…

#Imugene #Biotech #ClinicalTrials $IMU

“We know this is working in a late-stage patient population… with complete clearance of cancer in some patients.”

Encouraging signals continue from our azer-cel program, even in heavily pre-treated cases.

Our CEO Leslie Chong on Fear & Greed discussing the path forward.

Watch:
youtu.be/e9FsZ-nyG4c

$IMU #CancerResearch #Immunotherapy #CellTherapy #CART #Biotech #ClinicalTrials #Oncology #DrugDevelopment

Progress in biotech is built on collaboration between researchers, clinicians and industry.

No one works in isolation.

#Collaboration #Biotech #Research

Our CEO Leslie Chong speaking at the Bell Potter Healthcare Horizons Summit, alongside 15+ biotech companies presenting across the program.

A great opportunity to share updates on our progress as we continue to advance our clinical pipeline and immunotherapy technologies.

#Biotech #Healthcare #Immunotherapy

New Phase 1b Azer-cel trial data reports responses in additional blood cancers

Results from the CAR-T naïve cohort show:

• 100% ORR — CLL/SLL
• 80% ORR — marginal zone lymphoma

$IMU ASX announcement: imugene.com/investors/asx-…

#Imugene #BloodCancer #ClinicalTrials